Biocon Ltd

Nuvoco Vistas Corporation Ltd, Cipla Ltd, Aadhar Housing Finance Ltd, Alkem Laboratories Ltd are among the other stocks to see a surge in volumes on BSE today, 14 July 2026.Biocon Ltd saw volume of 473.28 lakh shares by 10:46 IST on BSE, a 224.63 fold spurt over two-week average daily volume of 2.11 lakh shares. The stock increased 7.08% to Rs.439.60. Volumes stood at 5.05 lakh shares in the last session.Nuvoco Vistas Corporation Ltd clocked volume of 8.72 lakh shares by 10:46 IST on BSE, a 56.34 times surge over two-week average daily volume of 15478 shares. The stock gained 7.81% to Rs.340.35. Volumes stood at 39713 shares in the last session.Cipla Ltd notched up volume of 8.18 lakh shares by 10:46 IST on BSE, a 17.21 fold spurt over two-week average daily volume of 47526 shares. The stock rose 1.42% to Rs.1,447.00. Volumes stood at 20923 shares in the last session.Aadhar Housing Finance Ltd notched up volume of 7.5 lakh shares by 10:46 IST on BSE, a 5.79 fold spurt over two-week average daily volume of 1.30 lakh shares. The stock slipped 2.50% to Rs.522.40. Volumes stood at 7.09 lakh shares in the last session.Alkem Laboratories Ltd notched up volume of 1.9 lakh shares by 10:46 IST on BSE, a 5.3 fold spurt over two-week average daily volume of 35790 shares. The stock slipped 0.28% to Rs.5,559.15. Volumes stood at 39767 shares in the last session.Powered by Capital Market - Live

Trading volumes surged significantly during the session. On the BSE, 4.72 crore shares changed hands compared with the three-month average of 2.49 lakh shares. On the NSE, 2.17 crore shares were traded, well above the three-month average of 41.40 lakh shares. According to media reports, U.S.-based Viatris-owned Mylan was looking to sell its entire 5.6% stake in the biotechnology company through block deals worth around Rs 3,481 crore. The transaction would mark Mylan's complete exit from Biocon after a 17-year partnership. The block deal was reportedly launched at a floor price of Rs 378.50 per share, a discount of 7.9% to Biocon's Monday closing price on the NSE. Mylan partnered with Biocon in 2009 to develop and commercialise biosimilars, later expanding the alliance to generic insulin analogues. It became a Biocon shareholder in January 2026 after Biocon issued shares as part of the acquisition of Viatris' stake in Biocon Biologics. The latest block deal would bring Mylan's association with Biocon to an end. As on June 2026, promoters held 44.67% stake in Biocon. Mylan Inc. held 5.64% in the company. Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases. On a consolidated basis, the company's net profit declined 63.4% year-on-year to Rs 126 crore in Q4 FY26 from Rs 344 crore in Q4 FY25. Revenue from operations increased 2.26% YoY to Rs 4,517 crore during the quarter. Powered by Capital Market - Live

The said contracts have been awarded to Duopharma (M) Sendirian Berhad, a wholly-owned subsidiary of Duopharma Biotech. As part of these contracts, Biocon's subsidiary, Biocon Sdn. Bhd., Malaysia, will supply short-acting recombinant human insulin, insulin glargine and insulin aspart to Duopharma (M) Sendirian Berhad for distribution. The contracts comprise a three-year agreement valued at MYR 155.27 million for human insulin, along with two two-year agreements, which consists of MYR 18 million contract for insulin glargine and MYR 52.5 million contract for insulin aspart. Shreehas Tambe, CEO & managing director, Biocon, said: 'Malaysia has been central to Biocon's insulin journey for over a decade, anchored by our integrated insulin manufacturing facility in the country ' the largest in Asia. Our Johor operations enable us to deliver insulin at scale, expanding patient access in Malaysia and around the world.' Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases. The company had reported 63.4% drop in consolidated net profit to Rs 126 crore in Q4 FY26 from Rs 344 crore in Q4 FY25. Revenue from operations rose by 2.26% year-on-year (YoY) to Rs 4,517 crore during the period under review. The scrip shed 0.17% to currently trade at Rs 422.65 on the BSE. Powered by Capital Market - Live

Biocon announced that its long-standing partner, Duopharma Biotech Berhad (Duopharma Biotech) via its wholly-owned subsidiary Duopharma (M) Sendirian Berhad, has secured multiple insulin contracts from the Ministry of Health (MoH), Malaysia, valued at over MYR 225 million this year. As part of these contracts, Biocon's subsidiary, Biocon Sdn. Bhd., Malaysia, will supply short-acting recombinant human insulin, insulin glargine and insulin aspart to Duopharma (M) Sendirian Berhad for distribution, supporting continued access to high-quality, cost-effective insulin therapies for people living with diabetes in Malaysia. The contracts comprise a three-year agreement valued at ~ MYR 155.27 million for human insulin, along with two 2-year agreements: ~ MYR 18 million for insulin glargine and ~ MYR 52.5 million for insulin aspart. In line with policies indicated in the 13th Malaysia Plan (RMK-13) and the New Industrial Master Plan 2030 (NIMP 2030), both companies are committed to helping patients with diabetes achieve better healthcare outcomes by ensuring a steady and accessible medicine supply.

Biocon announced that the 48th Annual General Meeting(AGM) of the company will be held on 6 August 2026.

Biocon Ltd gained for a fifth straight session today. The stock is quoting at Rs 430.55, up 2.76% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.33% on the day, quoting at 23767.5. The Sensex is at 75657.84, up 0.34%. Biocon Ltd has gained around 22.75% in last one month. Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has gained around 9.77% in last one month and is currently quoting at 24551.05, up 0.44% on the day. The volume in the stock stood at 56.13 lakh shares today, compared to the daily average of 46.75 lakh shares in last one month. The benchmark May futures contract for the stock is quoting at Rs 431.7, up 2.65% on the day. Biocon Ltd is up 26.86% in last one year as compared to a 5.01% slide in NIFTY and a 13.99% slide in the Nifty Pharma index.The PE of the stock is 285.14 based on TTM earnings ending March 26.Powered by Capital Market - Live

Biocon Ltd is up for a third straight session in a row. The stock is quoting at Rs 417.35, up 3.7% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.38% on the day, quoting at 23468.45. The Sensex is at 74886.66, up 0.44%. Biocon Ltd has added around 19.12% in last one month. Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has added around 6.63% in last one month and is currently quoting at 23840.9, up 0.34% on the day. The volume in the stock stood at 68.88 lakh shares today, compared to the daily average of 40.85 lakh shares in last one month. The benchmark May futures contract for the stock is quoting at Rs 419.55, up 3.75% on the day. Biocon Ltd is up 23.4% in last one year as compared to a 4.86% fall in NIFTY and a 11.37% fall in the Nifty Pharma index.The PE of the stock is 273.57 based on TTM earnings ending March 26.Powered by Capital Market - Live

Biocon Ltd is up for a fifth straight session today. The stock is quoting at Rs 386.7, up 1.16% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.67% on the day, quoting at 24164.3. The Sensex is at 77254.26, down 0.76%. Biocon Ltd has gained around 11.86% in last one month. Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has gained around 9.02% in last one month and is currently quoting at 24135.5, down 0.02% on the day. The volume in the stock stood at 42.2 lakh shares today, compared to the daily average of 29.37 lakh shares in last one month. The benchmark May futures contract for the stock is quoting at Rs 385.55, up 0.26% on the day. Biocon Ltd is up 17.22% in last one year as compared to a 0.65% jump in NIFTY and a 14.52% jump in the Nifty Pharma index.The PE of the stock is 318.83 based on TTM earnings ending December 25.Powered by Capital Market - Live

Revenue from operations rose by 2.26% year-on-year (YoY) to Rs 4,517 crore during the period under review. EBIDTA fell by 3.77% to Rs 1,073 crore while EBIDTA margin declined by 200 basis points YoY to 23% in Q4 FY26. Profit before tax in Q4 FY26 stood at Rs 248 crore, down by 49.2% from Rs 487 crore in Q4 FY25. For FY26, the company has recorded consolidated net profit and revenue from operations of Rs 386 crore (down 61.9% YoY) and Rs 16,927 crore (up 10.9% YoY), respectively. Kiran Mazumdar-Shaw, executive chairperson, Biocon, said: 'Biocon closed FY26 on a strong note despite a complex geopolitical environment. We delivered margin expansion along with 13% YoY growth in operating revenue, excluding the one-time impact of generic lenalidomide sales last year. This performance reflects the resilience of our business and disciplined execution through a pivotal year of integration. We have created a unified biopharma entity by integrating biosimilars business with generics formulations and APIs business. The combined business has a stronger balance sheet, improved leverage metrics and a more global commercial footprint. Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases. The scrip advanced 2.43% to currently trade at Rs 391.90 on the BSE. Powered by Capital Market - Live

Biocon announced that the Board of Directors of the Company at its meeting held on 7 May 2026, inter alia, have recommended the final dividend of Rs 0.5 per equity Share (i.e. 10%) , subject to the approval of the shareholders.